REG - Silence Therapeutics - Notice of half year results

Silence TherapeuticsAnnouncement

15/07/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210715:nRSO2870Fa&default-theme=true

RNS Number : 2870F  Silence Therapeutics PLC  15 July 2021

 

Silence Therapeutics Notice of Half Year Results

 

 

15 July 2021

 

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the
Company"), a leader in the discovery, development and delivery of novel short
interfering ribonucleic acid (siRNA) therapeutics for the treatment of
diseases with significant unmet medical need, today announced that the Company
will release its financial and business results for the half year ended June
30, 2021 on Thursday, August 12, 2021.

 

Management will host a conference call at 8:00 a.m. EDT / 13:00 BST that day
to discuss the Company's financial results and provide a general business
update. The conference call will be webcast live and will be available from
the Investors section of the Silence website, www.silence-therapeutics.com
(http://www.silence-therapeutics.com) . The webcast will also be archived on
the Company's website.

 

 

Details of the webcast and conference call:

 

Dial-in details:

New York, United States: +1 646 741 3167

United States: 1 877 870 9135

London, United Kingdom: +44 2071 928338

United Kingdom: 08002796619

 

Passcode: 9869230

 

Webcast link: https://edge.media-server.com/mmc/p/g85x6hug
(https://edge.media-server.com/mmc/p/g85x6hug)

 

 

Enquiries:

 

 Silence Therapeutics plc                               Tel:  +1 (646) 637-3208

 Gem Hopkins, Head of IR and Corporate Communications

 ir@silence-therapeutics.com

   Investec Bank plc (Nominated Adviser and Broker)       Tel:  +44 (0) 20 7597 5970

 Daniel Adams/Gary Clarence

 European PR                                            Tel: +44 (0) 20 3709 5700

 Consilium Strategic Communications

 Mary-Jane Elliott/ Angela Gray / Chris Welsh

 silencetherapeutics@consilium-comms.com

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing
the body's natural mechanism of RNA interference, or RNAi, to inhibit the
expression of specific target genes thought to play a role in the pathology of
diseases with significant unmet need. Silence's proprietary mRNAi GOLD™
platform can be used to create siRNAs (short interfering RNAs) that precisely
target and silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates include
SLN360 designed to address the high and prevalent unmet medical need in
reducing cardiovascular risk in people born with high levels of lipoprotein(a)
and SLN124 designed to address iron-loading anemia conditions. Silence also
maintains ongoing research and development collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information,
please visit https://www.silence-therapeutics.com/
(https://www.globenewswire.com/Tracker?data=UNZiZYHCIX53OcL8QavvjGyjNn3ybsba0Z8js3TZnoAJkSbT4n8JzaEjcBbkrikdBhBDB0Q6OmChtkU9RA6vE3RP-sL70Hdif0JPjsjT0-xuP4AZnQ7KIh_ri3BE5_7-1eQTwtukmxs5jZ9qKrr9Lg==)
.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGPUCAMUPGGRC